Brief: Index Pharmaceuticals Updates Timeline Of Phase III Study CONCLUDE

Flerie AB

27/01/2023 12:43

Jan 27 (Reuters) - InDex Pharmaceuticals Holding AB
 INDEX.ST :
    * INDEX PHARMACEUTICALS UPDATES THE TIMELINE OF THE PHASE
III
STUDY CONCLUDE WITH COBITOLIMOD
    * OUTCOME OF DOSE SELECTION EXPECTED TO BE AVAILABLE Q4,
2023

Source text for Eikon:  ID:nWkrbpTC1d 
Further company coverage:  INDEX.ST 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))